We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
The EORTC QLQ-CX24 cervical cancer-specific quality of life questionnaire: psychometric properties in a South Asian sample of cervical cancer patients.
Psycho-oncology 2008 October
OBJECTIVE: The cervical cancer-specific Quality of Life module of the European Organization for Research and Treatment of Cancer, EORTC QLQ-CX24, was recently validated in an international field study that did not include cervical cancer patients from South Asia. The aim of our study was to assess the psychometric properties of the instrument in a sample of cervical cancer patients from Sri Lanka to assess its suitability for use in the South Asian region.
METHODS: One hundred and twelve newly diagnosed patients with cervical cancer completed the translated version of the QLQ-CX24 in a cross-sectional validation study. Psychometric evaluation assessed the instrument for scale structure, scale reliability, validity and acceptability.
RESULTS: The QLQ-CX24 was found to be patient-friendly with high compliance and low missing data. Only a few patients needed assistance for completion. Overall results for multitrait scaling analysis confirmed the scale structure although some items of the symptom experience scale exhibited problems regarding item-scale correlations with its own scale. Cronbach's alpha coefficients for internal consistency ranging from 0.63 to 0.79 confirmed scale reliability. Construct validity was confirmed in two ways: the inter-scale correlations were statistically significant (p<0.01) and their magnitude moderate (r = 0.52-0.58) while the scales and single-item measures were able to discriminate between subgroups of patients differing with regard to treatment status.
CONCLUSION: The translated version of the QLQ-CX24 is a reliable and valid instrument to measure cervical cancer-specific Quality of Life in Sri Lanka. The overall results are in line with the findings of the international field study.
METHODS: One hundred and twelve newly diagnosed patients with cervical cancer completed the translated version of the QLQ-CX24 in a cross-sectional validation study. Psychometric evaluation assessed the instrument for scale structure, scale reliability, validity and acceptability.
RESULTS: The QLQ-CX24 was found to be patient-friendly with high compliance and low missing data. Only a few patients needed assistance for completion. Overall results for multitrait scaling analysis confirmed the scale structure although some items of the symptom experience scale exhibited problems regarding item-scale correlations with its own scale. Cronbach's alpha coefficients for internal consistency ranging from 0.63 to 0.79 confirmed scale reliability. Construct validity was confirmed in two ways: the inter-scale correlations were statistically significant (p<0.01) and their magnitude moderate (r = 0.52-0.58) while the scales and single-item measures were able to discriminate between subgroups of patients differing with regard to treatment status.
CONCLUSION: The translated version of the QLQ-CX24 is a reliable and valid instrument to measure cervical cancer-specific Quality of Life in Sri Lanka. The overall results are in line with the findings of the international field study.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app